Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 NMT Pharma and CAO Pharma Form Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

NMT Pharma and CAO Pharma Form Pact

Will further develop and market anti-cancer drug CZ-48

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Singapore-based NMT Pharmaceuticals Pte Ltd. has formed an agreement with U.S.-based CAO Pharmacueticals Inc. for acquiring an exclusive worldwide license right to further develop and market an anti-cancer drug CZ-48 co-developed by CAO Pharma and NMT Pharma.

NMT Pharma and CAO Pharma will enter into agreements that would secure funding needed by CAO Pharma to continue to operate and conduct clinical trials in the U.S. The collaboration is subjected to, among other requirements, satisfactory completion of due diligence and the execution of a definitive agreement.

CZ-48 is an analogue of camptothecin, which is stable and resistant to inactivation while circulating in human bloodstream. This topoisomerase I inhibitor only becomes active when entering in tumor cells. Based on preclinical and previous Phase I clinical trial data, CZ-48 has very low toxicity and mild side effects. CAO Pharma and NMT Pharma have improved the formulation of CZ-48 to increase the bioavailability of the drug so as to further reduce the side effects and improve therapeutic effects. CAO Pharma intends to restart the Phase I clinical study program with the new CZ-48 formulation within this year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics